Cipla invests extra $3 mn in Chase Pharmaceuticals

Chase Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders, including Alzheimer’s disease

id-100170733

Cipla UK's total investment in Chase would aggregate to approximately $5.12 million

"Cipla (EU) Limited, UK ("Cipla UK"), a wholly owned subsidiary of the Company, has pursuant to the approval of the board of Cipla UK, made an additional investment of $3 million in Chase Pharmaceuticals Corporation US ("Chase") towards full settlement of its obligation under the agreed arrangement for investment in Chase," Cipla said in a filing to BSE

"Consequently, Cipla UK's total investment in Chase would aggregate to approximately $5.12 million for a 16.7 percent stake on a fully diluted basis," it added.

The company in May 2014 had invested $1.5 million to acquire 14.6 percent stake in Chase Pharmaceuticals.

 

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X